Business Wire

PSA Certified Announces New PSA Certified Level 4 Certification and Continued Partner Growth

4.4.2024 11:00:00 EEST | Business Wire | Press release

Share

PSA Certified, the global security and evaluation framework for the connected device ecosystem, has today announced its highest certification level to date as it accelerates its mission to build assurance in connected devices. The new PSA Certified Level 4 iSE/SE certification offers enhanced protection of high value assets that can secure valuable AI models, future-proofing systems against new attack methods and rising security threats linked to the rapid adoption of edge AI. Its launch follows a period of strong momentum for PSA Certified which has become a trusted route for demonstrating security best practice and the assurance of connected devices.

David Maidment, Senior Director, Secure Devices Ecosystem at Arm (a PSA Certified co-founder):

As the world embraces a new set of AI-enabled use cases, the value of data and assets has never been higher; nor has the importance of protecting them. The launch of PSA Certified Level 4 iSE/SE is testament to our commitment to helping the industry deploy security features that will protect devices and models from malicious changes and theft now, as well as over the next decade.”

As security cements its position as a business imperative, forward-looking companies are uplevelling their investment in security-by-design. PSA Certified has now surpassed the milestone of 200 certifications from nearly 90 technology providers, making it one of the most successful schemes to address connected device security.

The newly launched PSA Certified Level 4 Integrated Secure Enclave / Secure Element (iSE/SE) certification, already available at PSA Certified Labs, builds on the scheme’s momentum further and underpins a step change that can be used to protect valuable models and data during device boot and at rest (when models reside in secure storage). The level recognizes the use of a highly robust integrated Secure Enclave (iSE) or Secure Element (SE) - that acts as a trusted subsystem to the full Root of Trust (PSA RoT). By safeguarding critical cryptographic functions and key storage, OEMs can now ask for a RoT with a trusted subsystem that offers a ‘high’ level of attack resistance.

Benefits of PSA Certified Level 4 iSE / SE Certification include:

Protecting ML models at rest with highly robust crypto and key storage

  • PSA Certified Level 4 iSE/SE considers more sophisticated attack methods in scope. Chips that achieve this new level could be used in an AI context to help protect valuable models and data at boot and rest: some chips will need protection from advanced fault injection and differential power analysis (up to and including EMFI, single laser and multi-glitching). PSA Certified Level 4 iSE/SE chips will also benefit from stronger cryptography of at least 128-bit strength. The new level offers a “high” level of protection of the PSA-RoT assets from physical or software attack.
  • A trusted subsystem that achieves PSA Certified Level 4 iSE/SE can be used through composition in a PSA Certified Level 3+SE certification of the full PSA RoT security functionality. The PSA Certified Level 3 document has been updated to allow this new certification level.

PSA Certified Level 4 iSE/SE will help protect emerging use cases from sophisticated security attacks

  • PSA Certified Level 4 iSE/SE offers additional security against more advanced attacks. Chips that offer this RoT provide a strong trust anchor that could be used to decrypt and verify OTA updates which help protect models in high-value systems.
  • Industrial and safety-critical use cases need to support system recovery and stronger authentication: re-establishing integrity, confidentiality and availability are fundamental when rebooting systems and deploying OTA updates when faults are found, or upgrades are required. PSA Certified iSE/SE also mandates higher strength cryptography, which protects against more sophisticated attacks.
  • Trust anchor for Edge AI and infrastructure chips, providing a “High” level of protection against physical and software attacks on critical assets that require a more robust Root of Trust to maintain system integrity.

A transparent certification scheme with a route to High, Substantial, and Basic levels of robustness and assurance, purpose-built for the SoC market

  • PSA Certified offers a variety of robustness levels to match the market’s needs, all specifically designed for the electronics industry. By allowing a trusted subsystem to be certified as a component, and that certificate reused as part of a complete PSA RoT many times, chip vendors benefit from significant time and cost savings.

The first partner to aim for the PSA Certified Level 4 iSE/SE standard is Infineon, showcasing its commitment to developing IoT devices to the highest security-by-design standards.

Erik Wood, Senior Director, IoT Secure MCU Products at Infineon comments:

“In the age of AI, the risks of insecurity are immense and increasing. I’ve backed PSA Certified since launch and I am impressed by its success in uniting the technology ecosystem around the common goal of improving trust and security within the connected device ecosystem, while aligning to emerging government standards and legislation. The launch of PSA Certified Level 4 iSE/SE takes that one step further. With this new level, the electronics industry is better able to protect against the growing advancement of attack methods driven by the explosion of machine learning, generative AI and LLM.”

About PSA Certified

PSA Certified is a global partnership of security-conscious companies who are proactively building security best practices into devices at scale. Our security framework and independent third-party evaluation scheme was originally spearheaded by Arm and six other security ecosystem leaders (and now maintained by Applus+ Laboratories, CAICT, ECSEC Laboratory, ProvenRun, Riscure, SGS Brightsight, Serma, TrustCB, and UL) providing the resources needed to build upon the Root of Trust.

PSA Certified has scaled to become one of the fastest growing, most valued security ecosystems, globally. Being awarded ‘Ecosystem of the Year’ in the IoT Global Awards 2021 is testament to the role it has played in uniting industry, standards bodies, regulators and insurers together under one initiative. In doing so it’s accelerating the cross-industry collaboration required to untap the full potential of the IoT.

With 200 certifications from 88 partners, PSA Certified has democratized the adoption of security across the electronics industry, giving the ecosystem the confidence to innovate, while protecting consumers from the most common hacks.

Find out more: psacertified.org

1 A Certified Security Report 2023

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

psacertified-uk@archetype.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye